urothelial cancer
FDA Approves Opdivo Qvantig for Subcutaneous Injection
The FDA approved nivolumab plus hyaluronidase-nvhy (Opdivo Qvantig, Bristol Myers Squibb) for subcutaneous ...
DECEMBER 30, 2024
FDA Approves Opdivo Combination for Unresectable or Metastatic Urothelial Carcinoma
The FDA approved Opdivo in combination with cisplatin and gemcitabine for first-line treatment of adult patients ...
MARCH 7, 2024
Padcev Approved for Some Patients With Locally Advanced or Metastatic Bladder Cancer
The FDA granted accelerated approval to enfortumab vedotin-ejfv (Padcev, Astellas/Seattle Genetics) for the ...
DECEMBER 20, 2019
Load more